APRE
Aprea Therapeutics, Inc. · Healthcare
Insiders bought $25K of Aprea Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
APRE over the last year
Largest buyers, last 12 months
APRE after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
31 insider filings since 2019, newest first
Marc Duey · Director
Marc Duey · Director
Bernd R. Seizinger · Director
Eyal C. Attar · SVP and Chief Medical Officer
Gregory Alan Korbel · SVP and Chief Business Officer
Gregory Alan Korbel · SVP and Chief Business Officer
Lars B. Abrahmsen · SVP and Chief Scientific Officer
Gregory Alan Korbel · SVP and Chief Business Officer
Gregory Alan Korbel · SVP and Chief Business Officer
Lars B. Abrahmsen · SVP and Chief Scientific Officer
Eyal C. Attar · SVP and Chief Medical Officer
Redmile Group, LLC · 10% owner
5Am Ventures Iv, L.P. · Former 10% holder
Kdev Investments Ab · 10% owner
Scott M Rocklage · Director and 10% owner
5Am Ventures Iv, L.P. · 10% owner
Scott M Rocklage · Director and 10% owner
5Am Ventures Iv, L.P. · 10% owner
Scott M Rocklage · Director
5Am Ventures Iv, L.P. · 10% owner
Kdev Investments Ab · 10% owner
5Am Ventures Iv, L.P. · 10% owner
Redmile Group, LLC · 10% owner
John B Henneman III · Director
Healthcap Vii, L.P. · 10% owner
Versant Vantage I, L.P. · 10% owner
V Luxco S.a R.l. Versant · 10% owner
Johan Christenson · Director
Guido Magni · Director
Scott M Coiante · SVP and CFO
Christian S Schade · President and CEO
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.